arrow
H

Haruhito Azuma

osaka medical and pharmaceutical university
H指数:48
被引数:7,866

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Author's reply to 'Bayesian interpretation of febrile neutropenia risk and primary G-CSF prophylaxis during darolutamide triplet therapy'

作者回复:“达罗鲁胺三联疗法期间发热性中性粒细胞减少症风险和初级G-CSF预防的贝叶斯解释”

2026-08-010
PRE
Comparative Efficacy of First-Line Immune Checkpoint Inhibitor-Based Combination Therapies in Patients With Sarcomatoid Renal Cell Carcinoma: A Japanese Multicenter Cohort Study

日本多中心队列研究:肉瘤样肾细胞癌患者一线免疫检查点抑制剂为基础的联合疗法的比较疗效

2026-05-010
OAAI
Discordance between PSA level and bone metastatic volume is associated with unfavourable prognosis

PSA水平与骨转移体积之间的不一致与不良预后相关

2025-11-010
PRE
Prognostic impact of lung metastasis in patients treated with androgen receptor signaling inhibitors for castration-sensitive prostate cancer: data from the ULTRA-Japan Consortium

去势敏感型前列腺癌患者接受雄激素受体信号抑制剂治疗后肺转移的预后影响: 来自超日本财团的数据

2025-10-010
PRE
Predictors of early progressive disease and antitumor effects by metastatic site in renal cell carcinoma treated with ipilimumab plus nivolumab

肾细胞癌患者接受伊匹木单抗联合纳武利尤单抗治疗时,早期进展性疾病及按转移部位的抗肿瘤效果的预测因子

2025-09-050
PRE
Mechanistic insights into lethal hyper progressive disease induced by PD-L1 inhibitor in metastatic urothelial carcinoma
2024-09-170
OAAI
C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma
2024-05-285
PRE
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors
2024-03-285
PRE
The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer
2023-11-1811
OAAI
Efficacy and Safety of Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Interim Analysis from a Multicenter, Open-label, Prospective Phase 2 Trial

膀胱保留疗法联合阿特珠单抗和放射疗法 (bpt-art) 治疗浸润性膀胱癌的疗效和安全性: 一项多中心,开放标签,前瞻性2期试验的中期分析

2023-11-018
OAAI
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma

pembrolizumab治疗铂难治性尿路上皮癌后的重新挑战化疗

2022-09-269
PRE
Site-specific Risk Stratification Models for Postoperative Recurrence and Survival Prediction in Patients with Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy: Better Stratification for Adjuvant Therapy
2022-07-012
OAAI